Chemexpress(SH:688131)2023-11-15 11:36Group 1: Company Overview - Shanghai Haoyuan Pharmaceutical Co., Ltd. is listed under stock code 688131 [1] - The company is engaged in the development and production of biological reagents and related services [3] Group 2: Financial Performance - In the first three quarters of 2023, the company achieved a revenue growth of 41.84% year-on-year, positioning it among the top CRO concept companies in China [3] - The increase in accounts receivable in Q3 2023 was primarily due to a rise in receivables from European distributors and slower payment from innovative drug clients [3] Group 3: Business Strategy - The company is focusing on expanding its product range in biological reagents and enhancing its market share through industrialization, globalization, and branding strategies [3] - Measures to improve profit margins include optimizing personnel structure and enhancing management of expenses, cash flow, inventory, and accounts receivable [3] Group 4: Future Outlook - The company aims to maintain high-speed and stable revenue growth while increasing the proportion of international business and high-margin revenue [3]